pharma · Metachromatic Leukodystrophy (MLD) · Mucopolysaccharidosis type I, Hurler Syndrome
ORCHARD THERAPEUTICS
Orchard Therapeutics (Netherlands) B.V.
ORCHARD THERAPEUTICS trial registry — 5 ClinicalTrials.gov studies with program phase, status, and indication context.
London, GB HQ
12 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- London, GB
- Employees
- 12
- Programs
- 5
- Drugs
- 12
- Patents
- 0
ORCHARD THERAPEUTICS clinical trials
Registry index of 5 ClinicalTrials.gov studies linked to ORCHARD THERAPEUTICS programs — each row shows trial ID, program name, phase, status, and indication.
ORCHARD THERAPEUTICS trial registry — 5 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for ORCHARD THERAPEUTICS.
-
OTL-203-02 — Phase 3
Clinical update -
TigetT10_MPSIH — Phase 2
Clinical update -
Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion — Phase 3
Clinical update -
Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion — Phase 3
Clinical update -
Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion — Phase 2
Clinical update
Trial registry
-
CTIS ↗ - 2024-511970-66-00CTIS ↗
Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion
Metachromatic Leukodystrophy (MLD)
- 2024-511971-13-00CTIS ↗
Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion
Metachromatic Leukodystrophy (MLD) is an autosomal recessive disorder caused by mutations
-
CTIS ↗ - 2024-515253-25-00CTIS ↗
Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion
Metachromatic Leukodystrophy (MLD)